Tarsons Products reported a 8% increase in annual revenue for FY26, reaching ₹423 crores, but profit after tax (PAT) declined due to escalating costs. Despite a 7% growth in domestic sales, export revenues were impacted by geopolitical difficulties. Cash PAT, however, saw a 21% year-over-year increase.

Tarsons Products' Q4 earnings showed a 7.5% drop in EBITDA compared to the previous year, with margins decreasing from 32.8% to 28.2%.

Tarson Products will convene a board meeting on May 22, 2026, to finalize and approve their audited financial results. The trading window for significant shareholders is currently closed and will remain so until 48 hours after the results are announced.

Tarsons Products announces the appointment of Mani Kalyan Dusi as the new revenue head for India and APAC regions. With over 18 years of experience in life sciences, pharmaceuticals, and academia, Mr. Dusi is expected to drive strategic growth for the company in these key markets.

Tarsons Products has invested €0.3 million in its Singapore subsidiary, with plans for a larger €3 million capital injection to settle outstanding loans and cover operational expenses.

Tarsons Products maintains a strong credit rating, as confirmed by CARE. Their long-term loan standing is rated 'CARE A' and considered stable. Similarly, short-term facilities have been rated 'CARE A1', following some adjustments in total limits due to both enhancements and reductions.